Abstract
Medical therapy of acromegaly with the somatostatin analog octreotide is very successful. Both clinical symptomatology and hormonal hypersecretion by the growth hormone-secreting pituitary adenomas are controlled, and peripheral IGF-I levels also return to near normal levels. Tumor shrinkage is observed in most patients. Somatostatin analogs can be used after noncurative surgery and for a limited period after radiotherapy, and octreotide pretreatment might improve the outcome of surgery.
MeSH terms
-
Acromegaly / drug therapy*
-
Adenoma / drug therapy
-
Adenoma / pathology
-
Adenoma / physiopathology
-
Growth Hormone / metabolism
-
Humans
-
Octreotide / administration & dosage
-
Octreotide / adverse effects
-
Octreotide / pharmacokinetics
-
Octreotide / therapeutic use
-
Pituitary Neoplasms / drug therapy
-
Pituitary Neoplasms / pathology
-
Pituitary Neoplasms / physiopathology
-
Receptors, Neurotransmitter / physiology
-
Receptors, Somatostatin
-
Somatostatin / analogs & derivatives*
Substances
-
Receptors, Neurotransmitter
-
Receptors, Somatostatin
-
Somatostatin
-
Growth Hormone
-
Octreotide